Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

Lilly welcomed NICE's decision and acknowledged the need for a phased introduction, but criticised the proposed timeline ... Wegovy (semaglutide) from Novo Nordisk in achieving weight loss.

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

The company created its GLP-1 Insurance Checker specifically to help you determine your coverage on popular weight loss drugs like Ozempic, Wegovy, and Zepbound. If you're new to Ro, they'll even ...

Consumer Reports warns that there are important considerations, especially for older adults, before starting these treatments ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Covering some 1.9million people in the UK, private health insurer Vitality has become the country’s first provider to offer customers discounted weight-loss treatments, such as Wegovy and Mounjaro.